4D·

Primary endpoint met in Corcept's pivotal Phase 3 ROSELLA trial of relacorilant in patients with ovarian cancer

$CORT (-6,42%)

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat serious endocrinologic, oncologic, metabolic and neurologic diseases by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company's pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, has met its primary endpoint of improved progression-free survival as determined by a blinded, independent pivotal review (PFS-BICR).


In the ROSELLA study, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy showed a 30 percent reduced risk of disease progression compared to patients receiving nab-paclitaxel alone (hazard ratio: 0.70; p-value: 0.008). Their median PFS-BICR was 6.5 months compared to 5.5 months in patients receiving nab-paclitaxel alone. In an interim assessment of overall survival (OS), patients treated with relacorilant plus nab-paclitaxel showed a significant improvement in OS with a median OS of 16.0 months compared to 11.5 months in patients receiving nab-paclitaxel alone (hazard ratio: 0.69; p-value: 0.012). Relacorilant was well tolerated and no new safety signals were observed. As in the company's Phase 2 study, safety and tolerability were comparable in both groups.


https://www.wallstreet-online.de/nachricht/19170527-primary-endpoint-met-corcept-s-pivotal-phase-3-rosella-trial-of-relacorilant-patients-with-platinum-resistant-ovarian-cancer

attachment
20
27 Comentários

imagem de perfil
Congratulations, both to the investors and to the patients who can be helped.
9
imagem de perfil
@Mark777
Thank you my dears, I am delighted as an investor @Semos25
1
imagem de perfil
@Tenbagger2024 When did you join the company? I've never heard of the company before.
imagem de perfil
@Semos25
Sometime last year. But I've also posted something about it from time to time.
2
imagem de perfil
@Tenbagger2024 very nice . Congratulations
1
Utilizador eliminado
4D
O comentário foi eliminado
imagem de perfil
@ChillmaldeineNuggets
Nice, with what ?
Utilizador eliminado
4D
O comentário foi eliminado
imagem de perfil
@ChillmaldeineNuggets
I see further potential here in the long term. Maybe it will even become a tenbagger. Stick with it for now.
1
imagem de perfil
@ChillmaldeineNuggets
How did you find out about the company?
Utilizador eliminado
4D
O comentário foi eliminado
Ver todas as 10 restantes respostas
imagem de perfil
1
imagem de perfil
@Max095
Thank you dear, you were once interested too. I always said it was a good alternative to Novo
1
imagem de perfil
@Tenbagger2024 You're right about that. I probably went with the trend too much. I hope $NOVO B will recover too
1
imagem de perfil
@Max095
It is always worth looking left and right.
1
@Tenbagger2024 I got in at €41.64 in October '24. You wrote so euphorically back then, it became a small gamble.
I'll probably take the stake out and let the rest run. Thanks for that :-)
imagem de perfil
@Ludaaa7
Oh my dear, that really makes me happy. I'm glad you read my post. You are a good person
Participar na conversa